Cited by 569Menopause: Health Impacts and TreatmentsVenous Thromboembolism Diagnosis and ManagementCerebral Venous Sinus Thrombosis

The DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index.

Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis

Open access

Canonico, Marianne, Plu-Bureau, Geneviève, Lowe, Gordon D O, Scarabin, Pierre-Yves·2008·BMJ

DOI 10.1136/bmj.39555.441944.bePMC PMC2405857

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVE: To assess the risk of venous thromboembolism in women using hormone replacement therapy by study design, characteristics of the therapy and venous thromboembolism, and clinical background. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Medline. STUDIES REVIEWED: Eight observational studies and nine randomised controlled trials. INCLUSION CRITERIA: Studies on hormone replacement therapy that reported venous thromboembolism. REVIEW MEASURES: Homogeneity between studies was analysed using chi(2) and I(2) statistics. Overall risk of venous thromboembolism was assessed from a fixed effects or random effects model. RESULTS: Meta-analysis of observational studies showed that oral oestrogen but not transdermal oestrogen increased the risk of venous thromboembolism. Compared with non-users of oestrogen, the odds ratio of first time venous thromboembolism in current users of oral oestrogen was 2.5 (95% confidence interval 1.9 to 3.4) and in current users of transdermal oestrogen was 1.2 (0.9 to 1.7). Past users of oral oestrogen had a similar risk of venous thromboembolism to never users. The risk of venous thromboembolism in women using oral oestrogen was higher in the first year of treatment (4.0, 2.9 to 5.7) compared with treatment for more than one year (2.1, 1.3 to 3.8; P<0.05). No noticeable difference in the risk of venous thromboembolism was observed between unopposed oral oestrogen (2.2, 1.6 to 3.0) and opposed oral oestrogen (2.6, 2.0 to 3.2). Results from nine randomised controlled trials confirmed the increased risk of venous thromboembolism among women using oral oestrogen (2.1, 1.4 to 3.1). The combination of oral oestrogen and thrombogenic mutations or obesity further enhanced the risk of venous thromboembolism, whereas transdermal oestrogen did not seem to confer additional risk in women at high risk of venous thromboembolism. CONCLUSION: Oral oestrogen increases the risk of venous thromboembolism, especially during the first year of treatment. Transdermal oestrogen may be safer with respect to thrombotic risk. More data are required to investigate differences in risk across the wide variety of hormone regimens, especially the different types of progestogens.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/bmj.39555.441944.be

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial
(2004) · JAMA · doi:10.1001/jama.291.14.1701 · Cited by 4,534
Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
QUANTITATIVE METHODS IN THE REVIEW OF EPIDEMIOLOGIC LITERATURE1
GREENLAND, S. (1987) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036298 · Cited by 1,644
Shape of the relapse curve and long-term abstinence among untreated smokers
Hughes, J. R., Keely, J., & Naud, S. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00540.x · Cited by 1,414
Antidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
Review papers : The statistical basis of meta-analysis
Fleiss, J. (1993) · Statistical Methods in Medical Research · doi:10.1177/096228029300200202 · Cited by 1,286
Effects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis
Herrington, D. M., Reboussin, D. M., Brosnihan, K. B., Sharp, P. C., Shumaker, S. A., Snyder, T. E., Furberg, C. D., Kowalchuk, G. J., Stuckey, T. D., Rogers, W. J., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008243430801 · Cited by 1,242
Postmenopausal Hormone Replacement Therapy: Scientific Review
Nelson, H. D., Humphrey, L. L., Nygren, P., Teutsch, S. M., & Allan, J. D. (2002) · JAMA · doi:10.1001/jama.288.7.872 · Cited by 990
A Clinical Trial of Estrogen-Replacement Therapy after Ischemic Stroke
Viscoli, C. M., Brass, L. M., Kernan, W. N., Sarrel, P. M., Suissa, S., & Horwitz, R. I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010534 · Cited by 919
Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women
Canonico, M., Oger, E., Plu‐Bureau, G., Conard, J., Meyer, G., Levesque, H., Trillot, N., Barrellier, M. ‐., Wahl, D. G., Emmerich, J., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.642280 · Cited by 867
Self-citation
Nicotine receptor partial agonists for smoking cessation
Hey, K., Lancaster, T., & Bala, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103 · Cited by 866
Risk of venous thromboembolism in users of hormone replacement therapy
Daly, E., Vessey, M. P., Hawkins, M. M., Carson, J. L., Gough, P., & Marsh, S. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07113-9 · Cited by 811
Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale.
Oger, E. (2000) · PubMed · Cited by 760
Understanding controlled trials: What are pragmatic trials?
Roland, M. O., & Torgerson, D. J. (1998) · BMJ · doi:10.1136/bmj.316.7127.285 · Cited by 704
Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk
Scarabin, P., Oger, E., & Plu‐Bureau, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14066-4 · Cited by 704
Self-citation
Estrogen plus progestin and risk of venous thrombosis
Cushman, M. (2004) · JAMA · doi:10.1001/jama.292.13.1573 · Cited by 632
Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
Jick, H., Derby, L. E., Myers, M. W., Vasilakis‐Scaramozza, C., & Newton, K. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07114-0 · Cited by 598
Prospective study of exogenous hormones and risk of pulmonary embolism in women
Grodstein, F., Stampfer, M. J., Goldhaber, S. Z., Manson, J. E., Colditz, G. A., Speizer, F. E., Willett, W. C., & Hennekens, C. H. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07308-4 · Cited by 570
Evidence from randomised trials on the long-term effects of hormone replacement therapy
Beral, V., Banks, E., & REEVES, G. K. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11032-4 · Cited by 484
Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Blood Coagulation and Fibrinolysis in Postmenopausal Women
Scarabin, P., Alhenc‐Gelas, M., Plu‐Bureau, G., Taisne, P., Agher, R., & Aiach, M. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.11.3071 · Cited by 346
Self-citation
Hormone replacement therapy and risk of venous thromboembolism: population based case-control study
Perez‐Gutthann, S., Rodriguez, L. A. G., Castellsagué, J., & Oliart, A. D. (1997) · BMJ · doi:10.1136/bmj.314.7083.796 · Cited by 336
Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial
Cherry, N., Gilmour, K., Hannaford, P. C., Heagerty, A. M., Khan, M. A., Kitchener, H. C., McNamee, R., Elstein, M., Kay, C. R., Seif, M. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)12001-0 · Cited by 333
Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
Emmerich, J., Rosendaal, F. R., Cattaneo, M., Margaglione, M., Stefano, V. D., Cumming, T., Arruda, V. R., Hillarp, A., & Reny, J. (2001) · PubMed · Cited by 325
Risk of vascular disease in women. Smoking, oral contraceptives, noncontraceptive estrogens, and other factors
Petitti, D. B. (1979) · JAMA · doi:10.1001/jama.242.11.1150 · Cited by 267
Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET).
Høibraaten, E., Qvigstad, E., Arnesen, H., Larsen, S. U., Wickström, E., & Sandset, P. (2000) · PubMed · Cited by 264
Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study
Rosing, J., Middeldorp, S., Curvers, J., Thomassen, S., Nicolaes, G. A. F., Meijers, J. C. M., Bouma, B. N., Buller, H. R., Prins, M. H., & Tans, G. (1999) · The Lancet · doi:10.1016/s0140-6736(99)06092-4 · Cited by 257
Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women
Vickers, M. R., MacLennan, A. H., LAWTON, B. A., Ford, D., Martin, J., Meredith, S. K., Stavola, B. L. D., Rose, S. B., Dowell, A. C., Wilkes, H. C., et al. (2007) · BMJ · doi:10.1136/bmj.39266.425069.ad · Cited by 255
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Womenʼs Health Initiative randomized controlled trial
(2003) · Obstetrics and Gynecology · doi:10.1097/00006250-200301000-00034 · Cited by 251
Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society
Utian, W. H., Archer, D. F., Bachmann, G. A., Gallagher, J. C., Grodstein, F., Heiman, J. R., Henderson, V. W., Hodis, H. N., Karaś, R., Lobo, R. A., et al. (2007) · Cited by 232
Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review
Wu, O., Robertson, L., Langhorne, P., Twaddle, S., Lowe, G. D. O., Clark, P., Greaves, M., Walker, I. D., Brenkel, I., Regan, L., et al. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-11-0759 · Cited by 221
Self-citation
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial
The Women's Health Initiative Steering Committee (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.06.061 · Cited by 220
Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus
Curb, J. D., Prentice, R. L., Bray, P. F., Langer, R. D., Horn, L. V., Barnabei, V. M., Bloch, M. J., Cyr, M. G., Gass, M. L. S., Lepine, L. A., et al. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.7.772 · Cited by 216
Postmenopausal Estrogen Replacement and Risk for Venous Thromboembolism
Miller, J., Chan, B. K. S., & Nelson, H. D. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-9-200205070-00011 · Cited by 203
Coagulation Activation Following Estrogen Administration to Postmenopausal Women
Caine, Y. G., Bauer, K. A., Barzegar, S., Cate, H. T., Sacks, F. M., Walsh, B. W., Schiff, I., & ROSENBERG, R. D. (1992) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646283 · Cited by 200
Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women
Straczek, C., Oger, E., Canonico, M., Plu‐Bureau, G., Conard, J., Meyer, G., Alhenc‐Gelas, M., Levesque, H., Trillot, N., Barrellier, M. ‐., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.565556 · Cited by 198
Self-citation
Estrogens, progestogens and thrombosis
Rosendaal, F. R., Vlieg, A. V. H., Tanis, B. C., & Helmerhorst, F. M. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00264.x · Cited by 189
Esterified Estrogens and Conjugated Equine Estrogens and the Risk of Venous Thrombosis
Smith, N. L. (2004) · JAMA · doi:10.1001/jama.292.13.1581 · Cited by 174
Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Sensitivity to Activated Protein C Among Postmenopausal Women
Oger, E., Alhenc‐Gelas, M., Lacut, K., Blouch, M., Roudaut, N., Kerlan, V., Collet, M., Abgrall, J., Aiach, M., Scarabin, P., et al. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000087141.05044.1f · Cited by 166
Self-citation
Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis
Rosendaal, F. R., Vessey, M. P., Rumley, A., Daly, E., Woodward, M., Helmerhorst, F. M., & Lowe, G. D. O. (2002) · British Journal of Haematology · doi:10.1046/j.0007-1048.2002.03356.x · Cited by 153
Self-citation
Factor V Leiden, Hormone Replacement Therapy, and Risk of Venous Thromboembolic Events in Women With Coronary Disease
Herrington, D. M., Vittinghoff, E., Howard, T. D., Major, D. A., Owen, J. D., Reboussin, D. M., Bowden, D. W., Bittner, V., Simon, J. A., Grady, D. G., et al. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000018301.91721.94 · Cited by 151
Effects of estrogen replacement on the progression of coronary artery atherosclerosis
Herrington, D. M., Beboussin, D. M., & Brosnihan, K. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(00)00172-0 · Cited by 151
Hormone Replacement Therapy and the Risk of Hospitalization for Venous Thromboembolism: A Population-based Study in Southern Europe
Varas‐Lorenzo, C., guez, L. A. G. A. R., Cattaruzzi, C., Troncon, M. G., Agostinis, L., & Perez‐Gutthann, S. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009461 · Cited by 145
Different Effects of Oral and Transdermal Hormone Replacement Therapies on Factor IX, APC Resistance, t-PA, PAI and C-reactive Protein
Upton, M. N., Rumley, A., McConnachie, A., O’Reilly, D., Watt, G. C. M., & Lowe, G. D. O. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616085 · Cited by 141
Self-citation
Effect of Oral and Transdermal Estrogen Replacement Therapy on Hemostatic Variables Associated With Venous Thrombosis
Post, M. S., Thomassen, S., Thomassen, S., van der Mooren, M. J., van Baal, W. M., Rosing, J., Kenemans, P., & Stehouwer, C. D. A. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000074146.36646.c8 · Cited by 131
Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study
Canonico, M., Oger, E., Conard, J., Meyer, G., Levesque, H., Trillot, N., Barrellier, M. ‐., Wahl, D. G., Emmerich, J., & Scarabin, P. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01933.x · Cited by 113
Self-citation
A Prospective Investigation of Pulmonary Embolism in Women and Men
Quinn, D. A. (1992) · JAMA · doi:10.1001/jama.1992.03490130077034 · Cited by 105
Making decisions about hormone replacement therapy
RYMER, J. M., Wilson, R., & Ballard, K. (2003) · BMJ · doi:10.1136/bmj.326.7384.322 · Cited by 95
Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double‐blind, placebo‐controlled trial
Høibraaten, E., Mowinckel, M., de Ronde, H., Bertina, R. M., & Sandset, P. M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03111.x · Cited by 92
Risk of Venous Thromboembolism in Users of Hormone Replacement Therapy
Daly, E., Vessey, M. P., Hawkins, M. M., Carson, J. L., Gough, P., & Marsh, S. (1997) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199705000-00020 · Cited by 91
Case-control study of venous thromboembolism risk in users of hormone replacement therapy
Daly, E., Vessey, M. P., Painter, R., & Hawkins, M. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)24041-3 · Cited by 74
Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case–control study
Douketis, J. D., Julian, J. A., Kearon, C., Anderson, D. R., Crowther, M. A., Bates, S. M., Barone, M., Piovella, F., Turpie, A. G. G., Middeldorp, S., et al. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01268.x · Cited by 74
Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease
Lowe, G. D. O. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01400.x · Cited by 54
Self-citation
Assessment of the Risk for Venous Thromboembolism Among Users of Hormone Replacement Therapy
Oger, E., & Scarabin, P. (1999) · Drugs & Aging · doi:10.2165/00002512-199914010-00004 · Cited by 44
Self-citation
Risk of Venous Thromboembolic Disease Associated With Hormonal Contraceptives and Hormone Replacement Therapy: A Clinical Review
Gomes, M. P. V., & Deitcher, S. R. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.18.1965 · Cited by 44
Postmenopausal hormone replacement therapy and venous thromboembolism
Wu, O. (2005) · Gender Medicine · doi:10.1016/s1550-8579(05)80061-0 · Cited by 43
Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - Pooled analysis of 8 case-control studies including 2310 cases and 3204 controls
Emmerich, J., Rosendaal, F. R., Cattaneo, M., Margaglione, M., De Stefano, V., Cumming, T., Arruda, V. R., Hillarp, A., & Reny, J. (2001) · Lund University Publications (Lund University) · Cited by 29
Differential AT III-response to oral and parenteral administration of 17 beta-estradiol.
Conard, J., Samama, M. M., Basdevant, A., Guy-grand, B., & Lignieres, B. D. (1983) · PubMed · Cited by 27
A prospective investigation of pulmonary embolism in women and men
Quinn, D. (1992) · JAMA · doi:10.1001/jama.268.13.1689 · Cited by 23
Conjugated Equine Estrogen, Esterified Estrogen, Prothrombotic Variants, and the Risk of Venous Thrombosis in Postmenopausal Women
Smith, N. L., Heckbert, S. R., Lemaître, R. N., Reiner, A. P., Lumley, T., Rosendaal, F. R., & Psaty, B. M. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000245792.62517.3b · Cited by 20
Are Some Types of Hormone Therapy Safer Than Others?
Rexrode, K. M., & Manson, J. E. (2007) · Circulation · doi:10.1161/circulationaha.106.675405 · Cited by 17
Postmenopausal hormone therapy and cardiovascular disease: An overview of main findings
Canonico, M., Straczek, C., Oger, E., Plu‐Bureau, G., & Scarabin, P. (2006) · Maturitas · doi:10.1016/j.maturitas.2006.04.019 · Cited by 16
Self-citation
Update on the Cardiovascular Risks of Hormone Replacement Therapy
Lowe, G. D. O. (2006) · Women s Health · doi:10.2217/17455057.3.1.87 · Cited by 12
Self-citation
Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus
(2006) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000209495.80866.96 · Cited by 11
Is the current classification of venous thromboembolism acceptable? No
WHITE, H., & Murin, S. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.01075.x · Cited by 9
Genetic aspects of venous thrombosis
Bertina, R. M. (2001) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/s0301-2115(00)00488-7 · Cited by 8
Women's Vascular Health
Greer, I. A., Ginsberg, J., & Forbes, C. (2006) · CRC Press eBooks · doi:10.1201/b13359 · Cited by 8
Estrogen Replacement Therapy and the Risk of Venous Thrombosis
Devor, M., Barrett-Connor, E. L., & Renvall, M. J. (1992) · The Endocrinologist · doi:10.1097/00019616-199207000-00019 · Cited by 4

Research works printed but not linked: 2

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12.
Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993;2:121-45.

Sorted by citations

ESHRE Guideline: management of women with premature ovarian insufficiency
The ESHRE Guideline Group on POI, Webber, L. J., Davies, M. C., Anderson, R. A., Bartlett, J., Braat, D. D. M., Cartwright, B., Cífková, R., Keizer‐Schrama, S. D. M., Hogervorst, E., et al. (2016) · Human Reproduction · doi:10.1093/humrep/dew027 · Cited by 1,603
Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner syndrome meeting
Gravholt, C. H., Andersen, N. H., Conway, G. S., Dekkers, O. M., Geffner, M. E., Klein, K. O., Lin, A. E., Mauras, N., Quigley, C. A., Rubin, K., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0430 · Cited by 1,101
The 2017 hormone therapy position statement of The North American Menopause Society
The North American Menopause Society (2017) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000921 · Cited by 1,042
2016 IMS Recommendations on women’s midlife health and menopause hormone therapy
Baber, R., Panay, N., & Fenton, A. J. (2016) · Climacteric · doi:10.3109/13697137.2015.1129166 · Cited by 968
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884

See all 569

Authors: Canonico, M., Plu-Bureau, G., Lowe, G. D. O., & Scarabin, P.-Y.
Affiliations: Université Paris-Sud (FR)
Glasgow Royal Infirmary (GB)
Corresponding author: Canonico, Marianne
ORCID: Canonico, Marianne
Lowe, Gordon D O
Scarabin, Pierre-Yves
Venue: BMJ
Publisher: BMJ
Published: 2008-05-20
Volume: 336
Issue: 7655
Pages: 1227-1231
ISSN: 0007-1447 (ISSN-L)
0959-8138
1468-5833
DOI: 10.1136/bmj.39555.441944.be
PMC: PMC2405857
OpenAlex: W2008660261
Cited by: 569
References: 73
Citations by year: 2026: 25 · 2025: 31 · 2024: 20 · 2023: 17 · 2022: 29 · 2021: 30 · 2020: 21 · 2019: 29 · 2018: 27 · 2017: 26 · 2016: 30 · 2015: 28 · 2014: 32 · 2013: 45 · 2012: 35
FWCI: 6.50
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.bmj.org/licenses/tdm/1.0/terms-and-conditions.html (tdm)
Locations: BMJ (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion, other-oa)
HighWire Press Open Archive (submittedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Clinical Neurology › Cerebral Venous Sinus Thrombosis
Keywords: hormone replacement therapy, venous thromboembolism, postmenopausal women, oral estrogen, transdermal estrogen, obesity, unopposed estrogen, progestogens, thrombosis risk, treatment duration
MeSH terms: Administration, Cutaneous, Administration, Oral, Female, Humans, Risk, Risk Factors, Estrogen Replacement Therapy, Randomized Controlled Trials as Topic, Postmenopause, Venous Thromboembolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks